Bevacizumab therapy in patients with recurrent uterine neoplasms.

Abstract

BACKGROUND:

Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms.

PATIENTS AND METHODS:

A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed.

RESULTS:

A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD).

CONCLUSION:

Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.

• Authors: Jason D Wright, Matthew A Powell, Janet S Rader, David G Mutch, Randall K Gibb
• Journal: Anticancer research (Anticancer Res) 2007 Sep-Oct Vol. 27 Issue 5B Pg. 3525-8 ISSN: 0250-7005 [Print] Greece
• PMID: 17972512 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adult
• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Demography
• Female
• Humans
• Incidence
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy, epidemiology)
• Retrospective Studies
• Treatment Outcome
• United States (epidemiology)
• Uterine Neoplasms (drug therapy, epidemiology)